Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data of control, doxorubicin and/or Y27632 treated HeLa cells

ABSTRACT: Expression data of control, doxorubicin and/or Y27632 treated HeLa cells

PROVIDER: PRJNA672689 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data from doxorubicin-treated Myxoid Liposarcoma cells and untreated control cells

Project description:Expression data from doxorubicin-treated Myxoid Liposarcoma cells and untreated control cells

| PRJNA435553 | ENA

Expression data from doxorubicin-treated Myxoid Liposarcoma cells and untreated control cells

Project description:Despite an improved survival of myxoid liposarcoma (MLS) patients, existing therapies have shortcomings including therapy resistance. To study the characteristics of therapy resistance in MLS, we treated three MLS cell lines with the commonly used chemotherapy drug doxorubicin and compared their gene expression profiles with untreated control cells.

2018-02-23 | GSE110997 | GEO

Expression data of control, doxorubicin and/or Y27632 treated HeLa cells

Project description:In the treatment of cancer with chemotherapeutics, it has been observed that a significant amount of cancer cells turn into senescent cells. These senescent cells secrete several factors in their microenvironment called SASP. Therefore, recently, to develop the senolytic and/or senomorphic drugs, targeting the senescent cells gains importance as a new strategy for preventing the damage that senescent cancer cells cause. In the current work, we evaluated whether Rho/Rho kinase pathway has a potential to be used as a target pathway for the development of senolytic and/or senomorphic drugs, in doxorubicin-induced senescent cancer cell lines. We performed a whole-genome microarray analysis to determine how the expressions of SASP factors change in senescent cells and whether ROCK inhibition also causes changes in the expression of these factors.

2021-04-13 | GSE160234 | GEO

Mouse cardiac tissue: Vehicle treated control vs. 15mg/kg doxorubicin

2010-08-06 | GSE17826 | GEO

Mouse cardiac tissue, polysomes and monosomes: Vehicle treated control vs. 15mg/kg doxorubicin

Project description:Translational profiling of mouse cardiac tissue treated with 15mg/kg doxorubicin in 10 ml/kg saline over an acute time course (0.5-120 hours) compared to time matched control animals treated with 10ml/kg saline.

2010-08-06 | GSE17823 | GEO

Timecourse on MCF-7 cells treated with different concentration of doxorubicin

Project description:MCF-7 cells treated with 10μM doxorubicin for 4h followed by subsequent withdrawl of the drug and cultured up to 48h.Doxurubicin-treated cells and control cells were collected at 0,12,24,36,and 48h. Meanwhile,MCF-7 cells continuously exposed to a low dosage of doxorubicin at 0.1μM for 96h. Doxorubicin-treated cells and control cells were collected at 0,24,48,72 and 96h.

2019-04-11 | ST001170 | MetabolomicsWorkbench

polyA-RNA-seq from mESC treated with doxorubicin

Project description:control vs doxorubicin treated mESC WT, p53 KO mESC, and Dux KO mESC

2021-05-21 | GSE149232 | GEO

ribo-seq in control and U1 AMO treated HeLa cells

Project description:ribo-seq in control and U1 AMO treated HeLa cells

| PRJNA795419 | ENA

Mouse cardiac tissue: Vehicle treated control vs. 15mg/kg doxorubicin

Project description:Transcriptional profiling of mouse cardiac tissue treated with 15mg/kg doxorubicin in 10 ml/kg saline over an acute time course (0.5-120 hours) compared to time matched control animals treated with 10ml/kg saline. Two colour microarrays with time matched controls against 15mg/kg doxorubicin cardiac tissue. Time points studied were 0.5, 1, 2, 12, 24 and 120 hours following dosing, biological replicates n=>3 independent animals at each time point, technical replicate n>1 with reverse labelling at each time point. One array printed onto two slides (A and B), one replicate per array.

2010-08-06 | E-GEOD-17826 | biostudies-arrayexpress

wdr33 iCLIP-seq in control and U1 AMO-treated HeLa cells

Project description:To understand the effect of U1 AMO treatment on wdr33 binding profile , we carried out CstF64 iCLIP-seq experiments in HeLa cells treated with either control or U1 AMO.

2023-02-27 | GSE193370 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data